Transcript
BBC Podcast Advertiser (0:00)
This BBC podcast is supported by ads outside the UK. The best B2B marketing gets wasted on the wrong people. So when you want to reach the right professionals, use LinkedIn ads. LinkedIn has grown to a network of over 1 billion professionals, including 130 million decision makers. And that's where it stands apart from other ad buyers. You can target your buyers by job title, industry, company role, seniority, skills, company revenue so you can stop wasting budget on the wrong audience. It's why LinkedIn Ads generates the highest B2B return on ad spend of major ad networks. Spend $250 on your first campaign on LinkedIn Ads and get $250 credit for the next one. Just go to LinkedIn.com Broadcast that's LinkedIn.com Broadcast. Terms and conditions apply. This message comes from Schwab at Schwab. How you invest is your choice, not theirs. That's why when it comes to managing your wealth, Schwab gives you more choices. You can invest and trade on your own. Plus get advice and more comprehensive wealth solutions to help meet your unique needs. With award winning service, low costs and transparent advice, you can manage your wealth your way at Schwab. Visit schwab.com to learn more.
Michelle Fleury (1:18)
Hello and welcome to Business Daily from the BBC World Service. I'm Michelle Fleury and today I'm asking for what's really behind the biohacking fad, why people are doing it, what exactly they think they're upgrading.
Teresa Lollie (1:31)
It works for our family. Every day we wake up and we understand the bullets that we dodged.
Michelle Fleury (1:36)
Biohackers say they're making their bodies and brains run better by hacking their biology. And it's not just kitchen counter experimentation anymore. There's now an entire industry promising to optimize you with supplements, treatments and increasingly strange gadgets. And because I'm lazy, I'm trying a treatment that claims it can work out my body for me.
Anthony Lollie / Chuck Morris (1:58)
We can give you 5,000 crunches in 10 minutes.
Michelle Fleury (2:03)
But a lot of these methods are controversial and none of them have been proven to extend anyone's lifetime. In real, well designed clinical trials they're.
Dr. Nir Barzilai (2:12)
Using maybe unconventional or unproven treatment that could be also dangerous.
Michelle Fleury (2:18)
So is the business of biohacking brilliant or just bonkers? That's coming up on today's Business Daily. Biohacking is when ordinary people start treating their bodies like machines, tweaking sleep, diet and exercise, tracking every metric and trying to slow down aging in the process. It's a fast growing industry blending medicine technology and AI technology, now worth an estimated $17 billion with luxury brands racing to cash in. High end gym chain in the United States. Equinox is the Latest launching a $40,000 longevity membership later this year. On social media, the trend is everywhere. Influencers promise that real time personalised data can optimise everything from performance to lifespan. Among the most prominent are the Lolli family.
